Schering AG/Epix Imaging Agent Requires Additional Clinical Studies – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG/Epix MS-325 imaging agent requires additional clinical studies, FDA says in “approvable” letter. Outstanding questions relate to the non-contrast comparator scanning methods used in Phase III trials and statistical treatment of uninterpretable baseline scans